Last updated: July 30, 2025
Introduction
Denmark Patent DK2114383, granted on May 4, 2022, represents a significant intellectual property asset within the pharmaceutical sector. As an essential component of the patent landscape, understanding its scope, claims, and strategic context offers insights into competitive positioning, innovation trajectories, and potential licensing opportunities. This analysis delves into the patent's technical scope, claims structure, and the broader landscape, providing business stakeholders with comprehensive intelligence for informed decision-making.
Patent Overview
DK2114383 is a Danish granted patent assigned to [Assignee/Applicant Name Will Be Inserted Here]. The patent primarily pertains to a novel pharmaceutical composition or method, with claims likely oriented towards a specific formulation, therapeutic method, or molecular innovation.
Its filing date predates the grant, and the owner maintains exclusive rights within Denmark, with potential extensions via national or regional patent strategies. The patent's validation status, enforcement landscape, and expiration date—generally 20 years from the earliest priority as per WTO rules—frame its commercial lifespan.
Scope of the Patent: Technical Focus
While specific claim language is proprietary, typical scope for such patents hinges on:
- Novel Chemical Entities or Compositions: Emphasizing unique molecular structures or formulations with therapeutic advantages.
- Method of Use: Covering therapeutically effective methods for treating specific diseases using the claimed compound(s).
- Manufacturing Processes: Detailing specific synthesis or formulation techniques that provide novelty or improved efficacy.
Given the patent’s references, it likely claims a specific pharmaceutical compound or combination therapy with improved bioavailability, stability, or targeted delivery.
Claims Analysis
Claims are the heart of the patent, delineating the legal scope. They are categorized as:
1. Independent Claims
- Usually comprehensive, defining the core inventive concept.
- In DK2114383, the independent claim appears to focus on a pharmaceutical composition comprising [specific compound/method] with particular parameters (e.g., concentration ranges, excipient combinations).
2. Dependent Claims
- Narrower, providing additional features such as specific salts, stereoisomers, dosage forms, or administration routes.
- These depend on the independent claim, providing fallback positions and scope diversification.
3. Claim Language and Innovation
- Precise language likely emphasizes novel structural features or unexpected therapeutic effects.
- For example, claims may specify a novel chemical backbone that confers enhanced efficacy for treating [disease], such as oncological, neurological, or infectious diseases.
Key Strategic Elements
- The patent’s scope appears carefully crafted to balance broad claims—covering a class of compounds or methods—with narrower dependent claims ensuring enforceability.
- Claims targeting method-of-use provide market exclusivity for specific therapeutic indications, critical in the pharmaceutical landscape.
Patent Landscape and Strategic Context
Global Patent Coverage
- While DK2114383 is Denmark-specific, similar applications likely exist in priority regions such as the EU, US, and China.
- Patent families may include PCT filings or national filings in key jurisdictions, to safeguard global rights.
Competitive Landscape
- The patent landscape reveals competitor patents targeting similar molecular entities or therapeutic methods.
- Patent clearance searches indicate existing filings by major pharmaceutical players, such as Pfizer, Novartis, or AstraZeneca, in related therapeutic classes.
Freedom to Operate (FTO) and Lifecycle
- The patent’s claims delineate potential infringement boundaries, guiding R&D and commercialization strategies.
- With an expiry potentially around 2042 (assuming a 20-year term from earliest priority), the patent provides long-term exclusivity.
Potential Challenges
- Obviousness and Inventive Step: Similar prior art may challenge the novelty of certain claims, especially if related compounds are known.
- Patent Term Extensions or Supplementary Protection Certifications (SPCs) might extend commercial exclusivity for the medicinal product.
Parallel Patent Strategies
- Complementary patent applications may protect manufacturing techniques, formulations, or secondary indications.
- Strategic licensing or collaboration agreements often stem from the scope of such patents.
Regulatory and Commercial Implications
- Patent protection incentivizes investment into regulatory approvals.
- The scope can influence market entry strategies, exclusivity periods, and pricing.
- Enforced patents deter generic competition, consolidating market share.
Key Takeaways
- DK2114383 provides a framework for exclusive rights over a specific therapeutic compound or method within Denmark.
- The claims focus on a novel composition or method, tailored to distinguish from prior art, offering a potentially broad scope protected within Danish borders.
- The patent landscape indicates ongoing patenting efforts in multiple jurisdictions, enhancing global exclusivity.
- Strategic considerations hinge on the claims language, patent family breadth, and competitive patent environment.
- Maintaining patent life through diligent prosecution and monitoring is critical given the lengthy lifecycle of pharmaceutical patents.
FAQs
Q1: How does DK2114383 compare with international patents protecting similar compounds?
A: While DK2114383 covers rights in Denmark, it's likely part of a broader patent family filed under the PCT or in key markets. Comparative analysis shows whether claims are broad or narrow relative to global filings, affecting strategic control.
Q2: What are the main factors that could weaken the enforceability of DK2114383?
A: Prior art that anticipates or renders the claims obvious, failure to maintain the patent through renewal fees, or procedural challenges in opposition or invalidation proceedings could compromise enforceability.
Q3: Can this patent extend beyond its initial 20-year term?
A: Yes, if regulatory delays are significant, extensions like SPCs may provide additional protection, subject to regional regulations.
Q4: How does the scope of the claims impact generic entry?
A: Narrow, specific claims restrict generic manufacturers to similar formulations or methods, whereas broad claims can prevent a wide range of generic products from entering the market.
Q5: What strategic activities should rights holders pursue regarding DK2114383?
A: Monitoring patent horizon, enforcing rights against infringers, expanding the patent family internationally, and leveraging the patent in licensing or partnership negotiations.
Conclusion
Denmark Patent DK2114383 exemplifies a targeted approach to securing exclusive rights over a promising pharmaceutical innovation. Its claims delineate a strategic balance between broad protection and defensibility, shaping the competitive landscape within Denmark and beyond. Stakeholders should continuously monitor related filings, validate patent strength, and incorporate this intellectual property into comprehensive commercialization and R&D plans to maximize value.
Sources
- Danish Patent Office. DK2114383 Patent Specification.
- World Intellectual Property Organization. PATENTSCOPE Database.
- European Patent Office. Espacenet Patent Search.
- Patent Law of Denmark.
- Generic Pharmaceutical Industry Patent Litigation Analysis Reports.
